 Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced that Brian M. Culley, Chief Executive Officer, will be presenting tomorrow morning at the 2020 Raymond James Human Health Innovation Conference at 9:40 am Eastern Time. In addition to a corporate overview, Mr. Culley will provide an update on the status of Lineages lead program, OpRegen, an allogeneic retinal pigment epithelium RPE transplant therapy for dry age-related macular degeneration AMD. Recently, the company provided details on the first known reported finding of retinal tissue regeneration in a patient with dry AMD with geographic atrophy. Interested investors can access the live presentation on the Events and Presentations section of Lineages website. 